Skip to main content
. Author manuscript; available in PMC: 2014 Apr 22.
Published in final edited form as: Cancer Res. 2012 Nov 19;73(2):834–843. doi: 10.1158/0008-5472.CAN-12-2066

Figure 6. Mechanisms of resistance to EGFR TKIs in PC9 cells.

Figure 6

Treatment of PC9 cells with reversible quinazoline-based TKIs (upper line) or clinical concentrations of irreversible TKI (middle line) leads to emergence of the EGFR T790M mutation as a mechanism of resistance. Treatment with a T790M -potent EGFR TKI (bottom line) prevents emergence of the EGFR T790M mutation and results in a sequential acquisition of non-T790M resistance mechanisms involving IGF1R and MAPK pathways.